Elijah

Born: 2012
Parent: Giorgia

His Story:

Diagnosed with KCNA2 in 2017

Elia was born in 2012 with spontaneous and full-term delivery. She had her first episodes of seizures at five months with generalized focal seizures during the falling asleep phase. We made several hospitalizations with two resonances with nothing evident and three genetic studies. Elia found it very difficult to find medicines that would make her overcome the crises, She immediately became drug resistant. After many attempts at medicines we managed to reset the seizures with a cycle of ACTH, after which she started reacting to the medicines. Now she takes Depakin, rivotril, taloxa and tyrosint being hypothyroid. We discovered her genetic problem in 2017 and she was the 24th case. Now Elia has seizures under control, she has ataxia and cognitive impairment but her development is advancing and we are very happy. We are not yet aware of its case history, it is thought to be a loss of function but it is not yet certain.

Elia è nato nel 2012 con parto spontaneo e a termine. Ha avuto i primi episodi di crisi epilettiche a cinque mesi con crisi focali generalizzate durante la fase dell’ addormentamento. Fatti diversi ricoveri con due risonanze con nulla di evidente e tre studi genetici. Elia ha trovato parecchie difficoltà a trovare medicinali che gli facessero passare le crisi, diventava subito farmaci resistente. Dopo tanti tentativi di medicinali siamo riusciti a fare un reset delle crisi epilettiche con un ciclo di ACTH ,dopo di ché ha iniziato a reagire ai medicinali. Ora prende Depakin,rivotril, taloxa e tirosint essendo ipotiroideo.Abbiamo scoperto il suo problema genetico nel 2017 e lui era il ventiquattresimo caso. Ora Elia ha le crisi sotto controllo, ha un’ atassia e deficit cognitivo ma il suo sviluppo sta avanzando e noi siamo molto contenti.
Non siamo ancora a conoscenza della sua casistica, si pensa sia una perdita di funzione ma non è ancora certa.

How She’s Doing Now

Elia currently takes Depakin, Rivotril, Taloxa, and Tyrosint (for hypothyroidism). Her seizures are now under control. She continues to live with ataxia and cognitive impairments, but her development is steadily progressing, and her family is deeply grateful for how far she has come.

What He’s Taught Us:

Elia’s journey has shown us how fragile, powerful, and surprising progress can be. Even when answers were scarce and setbacks constant, she kept moving forward, and so did we.

Therapies & Equipment:

ACTH therapy to reset seizure activity Anti-epileptic medications: Depakin, Rivotril, Taloxa Tyrosint for hypothyroidism Ongoing neurological and developmental monitoring Support for ataxia and cognitive delays Continued genetic review for mutation classification

Therapies & Equipment:

ACTH therapy to reset seizure activity Anti-epileptic medications: Depakin, Rivotril, Taloxa Tyrosint for hypothyroidism Ongoing neurological and developmental monitoring Support for ataxia and cognitive delays Continued genetic review for mutation classification
Scroll to Top